Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aura Biosciences Inc
(NQ:
AURA
)
7.590
+0.200 (+2.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aura Biosciences Inc
< Previous
1
2
Next >
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
June 22, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
June 17, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
May 26, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
May 25, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
May 12, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
May 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
May 03, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
March 23, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
March 21, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
March 15, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference
February 28, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
February 14, 2022
From
Aura Biosciences Inc.
Via
Business Wire
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021
From
Aura Biosciences, Inc.
Via
Business Wire
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting
November 15, 2021
From
Aura Biosciences
Via
Business Wire
Aura Biosciences Announces Pricing of Initial Public Offering
October 28, 2021
From
Aura Biosciences, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.